Tjitske Kleefstra1,2, Simon E Fisher3,4, Lot Snijders Blok5,6,7, Arianna Vino8, Joery den Hoed8, Hunter R Underhill9, Danielle Monteil10, Hong Li11, Francis Jeshira Reynoso Santos12,13, Wendy K Chung14, Michelle D Amaral15, Rhonda E Schnur16, Teresa Santiago-Sim16, Yue Si16, Han G Brunner1,2,17. 1. Human Genetics Department, Radboud University Medical Center, Nijmegen, The Netherlands. 2. Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands. 3. Language & Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen, The Netherlands. simon.fisher@mpi.nl. 4. Donders Institute for Brain, Cognition & Behaviour, Radboud University, Nijmegen, The Netherlands. simon.fisher@mpi.nl. 5. Human Genetics Department, Radboud University Medical Center, Nijmegen, The Netherlands. lot.snijdersblok@radboudumc.nl. 6. Language & Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen, The Netherlands. lot.snijdersblok@radboudumc.nl. 7. Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands. lot.snijdersblok@radboudumc.nl. 8. Language & Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen, The Netherlands. 9. Department of Pediatrics, Division of Medical Genetics, University of Utah, Salt Lake City, UT, USA. 10. Department of Pediatrics, Naval Medical Center, Portsmouth, VA, USA. 11. Department of Human Genetics, Emory University, Atlanta, GA, USA. 12. Department of Genetics, Joe DiMaggio Children's Hospital, Hollywood, FL, USA. 13. Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, USA. 14. Department of Pediatrics, Columbia University Irving Medical Center, New York, NY, USA. 15. HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA. 16. GeneDx, Gaithersburg, MD, USA. 17. Department of Clinical Genetics, MHeNS School of Neuroscience, and GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
Abstract
PURPOSE: Heterozygous pathogenic variants in various FOXP genes cause specific developmental disorders. The phenotype associated with heterozygous variants in FOXP4 has not been previously described. METHODS: We assembled a cohort of eight individuals with heterozygous and mostly de novo variants in FOXP4: seven individuals with six different missense variants and one individual with a frameshift variant. We collected clinical data to delineate the phenotypic spectrum, and used in silico analyses and functional cell-based assays to assess pathogenicity of the variants. RESULTS: We collected clinical data for six individuals: five individuals with a missense variant in the forkhead box DNA-binding domain of FOXP4, and one individual with a truncating variant. Overlapping features included speech and language delays, growth abnormalities, congenital diaphragmatic hernia, cervical spine abnormalities, and ptosis. Luciferase assays showed loss-of-function effects for all these variants, and aberrant subcellular localization patterns were seen in a subset. The remaining two missense variants were located outside the functional domains of FOXP4, and showed transcriptional repressor capacities and localization patterns similar to the wild-type protein. CONCLUSION: Collectively, our findings show that heterozygous loss-of-function variants in FOXP4 are associated with an autosomal dominant neurodevelopmental disorder with speech/language delays, growth defects, and variable congenital abnormalities.
PURPOSE: Heterozygous pathogenic variants in various FOXP genes cause specific developmental disorders. The phenotype associated with heterozygous variants in FOXP4 has not been previously described. METHODS: We assembled a cohort of eight individuals with heterozygous and mostly de novo variants in FOXP4: seven individuals with six different missense variants and one individual with a frameshift variant. We collected clinical data to delineate the phenotypic spectrum, and used in silico analyses and functional cell-based assays to assess pathogenicity of the variants. RESULTS: We collected clinical data for six individuals: five individuals with a missense variant in the forkhead box DNA-binding domain of FOXP4, and one individual with a truncating variant. Overlapping features included speech and language delays, growth abnormalities, congenital diaphragmatic hernia, cervical spine abnormalities, and ptosis. Luciferase assays showed loss-of-function effects for all these variants, and aberrant subcellular localization patterns were seen in a subset. The remaining two missense variants were located outside the functional domains of FOXP4, and showed transcriptional repressor capacities and localization patterns similar to the wild-type protein. CONCLUSION: Collectively, our findings show that heterozygous loss-of-function variants in FOXP4 are associated with an autosomal dominant neurodevelopmental disorder with speech/language delays, growth defects, and variable congenital abnormalities.
Entities:
Keywords:
FOXP4; congenital diaphragmatic hernia; de novo variants; neurodevelopmental disorder; speech/language disorder
Authors: David L Rousso; Caroline Alayne Pearson; Zachary B Gaber; Amaya Miquelajauregui; Shanru Li; Carlos Portera-Cailliau; Edward E Morrisey; Bennett G Novitch Journal: Neuron Date: 2012-04-26 Impact factor: 17.173
Authors: Fadi F Hamdan; Hussein Daoud; Daniel Rochefort; Amélie Piton; Julie Gauthier; Mathieu Langlois; Gila Foomani; Sylvia Dobrzeniecka; Marie-Odile Krebs; Ridha Joober; Ronald G Lafrenière; Jean-Claude Lacaille; Laurent Mottron; Pierre Drapeau; Miriam H Beauchamp; Michael S Phillips; Eric Fombonne; Guy A Rouleau; Jacques L Michaud Journal: Am J Hum Genet Date: 2010-10-14 Impact factor: 11.025
Authors: Jacqueline M Ehrman; Paloma Merchan-Sala; Lisa A Ehrman; Bin Chen; Hee-Woong Lim; Ronald R Waclaw; Kenneth Campbell Journal: J Neurosci Date: 2022-03-10 Impact factor: 6.709
Authors: Matteo D'Antonio; Jennifer P Nguyen; Timothy D Arthur; Hiroko Matsui; Agnieszka D'Antonio-Chronowska; Kelly A Frazer Journal: Cell Rep Date: 2021-11-03 Impact factor: 9.995